Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)
Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading